Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence
of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and …

Abstract Purpose of Review The epidemiology of antiphospholipid syndrome (APS) is poorly
understood. Here, we review the current understanding of the epidemiology of …

Patients with COVID-19 are at high risk for thrombotic arterial and venous occlusions. Lung
histopathology often reveals fibrin-based blockages in the small blood vessels of patients …

Background High incidence of thrombosis in COVID‐19 patients indicates a
hypercoagulable state. Hence, exploring the involvement of antiphospholipid antibodies …

Currently, we use the classification criteria for antiphospholipid syndrome (APS) formulated
during the consensus conference in Sapporo and revised in Sydney 1. Classification criteria …

Antiphospholipid syndrome is an autoimmune disorder characterized by vascular
thrombosis and/or pregnancy morbidity associated with persistent antiphospholipid antibody …

First described in the early 1980s, antiphospholipid syndrome (APS) is a unique form of
acquired autoimmune thrombophilia in which patients present with clinical features of …

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by
arterial and venous thrombotic manifestations and/or pregnancy-related complications in …

Accumulating evidence shows that SARS‐CoV‐2 can potentially trigger autoimmune
processes, which can be responsible for the long‐term consequences of COVID‐19 …

Current classification criteria for definite Antiphospholipid Syndrome (APS) require the use
of three laboratory assays to detect antiphospholipid antibodies (aCL, anti-β2GPI and LA) in …